Remove FDA Remove Pharma Remove Physicians Remove Side effects
article thumbnail

Projections on pharma digital ad spending wrong

World of DTC Marketing

GOOD MORNING: eMarketer is promoting a report on pharma’s projected digital ad spending in the coming year, and from my conversations with pharma insiders, it’s wrong. While some media outlets are saying that a COVID-19 vaccine can help pharma’s reputation I believe that is wishful thinking.

Pharma 180
article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Source: Fierce Pharma If that enthusiasm pans out in the long run, it could mean at least 300,000 patients taking the drug, or $10 billion to $15 billion in peak Aduhelm from U.S. One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S. history.”

FDA 218
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is it too late for Biogen?

World of DTC Marketing

Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. The question that has to be asked is how will physicians respond to this drug if approved?

article thumbnail

A realistic view of healthcare in 2022

World of DTC Marketing

1ne: The value proposition of prescription drugs still outweighs potential side effects – Wegovy’s demand quickly exceeded supply after the FDA approved once-weekly semaglutide injections. 3hree: Pharma will increase its spending in digital, but a lot of the money will be wasted.

article thumbnail

Why DTC isn’t, and is, marketing

World of DTC Marketing

But, in pharma marketing, the changes affect every product category. DTC pharma marketers must acknowledge that people’s days of seeing a TV ad and running to their doctor to ask for the product are all but gone. While trust in the pharma industry got a bump because of COVID vaccines, confidence about new drugs remains mixed.

Marketing 252
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

The FDA needs to study what people do when they see a DTC ad. They research the drug online and ask their physician about it if they decide it’s a treatment option. ” Patients want to understand how the drug works and the potential side effects before starting therapy. DTC ads do NOT lead to unnecessary Rxs.

Marketing 285
article thumbnail

FDA accepts Ardelyx’s NDA resubmission for XPHOZAH

Pharma Leaders

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.